Minerva Biotech

Minerva Biotechnologies is a clinical-stage biopharmaceutical company pioneering novel therapies in oncology and regenerative medicine. The company's research is centered on MUC1*, a truncated form of the MUC1 protein that functions as a critical growth factor receptor in cancer cells and pluripotent stem cells. Minerva is currently advancing a first-in-class CAR-T therapy, huMNC2-CAR44, which targets the MUC1* receptor for the treatment of metastatic breast cancer and other solid tumors. Beyond oncology, the company utilizes its MUC1* and NME7 technology to develop advanced platforms for the generation and maintenance of induced pluripotent stem cells (iPSCs). By targeting the fundamental mechanisms of cell growth and pluripotency, Minerva aims to address significant unmet needs in cancer treatment and cell-based therapies. The company's platform also includes the development of small molecule inhibitors designed to block the MUC1* signaling pathway in various malignancies.